Clinical characteristics of patients whose samples were used in this analysis
| . | GVHD . | NONE . | P . | |
|---|---|---|---|---|
| n | 26 | 27 | ||
| Disease, n (%) | .35 | |||
| AML | 17 (65) | 11 (41) | ||
| ALL | 3 (12) | 5 (19) | ||
| Lymphoma | 4 (15) | 8 (30) | ||
| Other | 2 (8) | 3 (11) | ||
| Conditioning, n (%) | .91 | |||
| Myeloablative | 11 (42) | 11 (41) | ||
| Reduced intensity | 15 (58) | 16 (59) | ||
| Donor, n (%) | .21 | |||
| Related | 17 (65) | 13 (48) | ||
| Unrelated | 9 (35) | 14 (52) | ||
| GVHD ppx, n (%) | .40 | |||
| CNI/MTX | 13 (50) | 17 (63) | ||
| CNI/ATG/ MTX | 7 (27) | 5 (19) | ||
| CNI/Siro ± MTX | 4 (15) | 5 (19) | ||
| Other* | 2 (8) | 0 (0) | ||
| Day of sample after HCT or DLI, median (range) | 47 (23-183) | 73 (20-98) | .14 | |
| GVHD | Gut (n = 12) | Skin (n = 14) | ||
| Grade 1 | 1 | 0 | ||
| Grade 2 | 8 | 6 | ||
| Grade 3 | 0 | 8 | ||
| Grade 4 | 3 | 0 | ||
| . | GVHD . | NONE . | P . | |
|---|---|---|---|---|
| n | 26 | 27 | ||
| Disease, n (%) | .35 | |||
| AML | 17 (65) | 11 (41) | ||
| ALL | 3 (12) | 5 (19) | ||
| Lymphoma | 4 (15) | 8 (30) | ||
| Other | 2 (8) | 3 (11) | ||
| Conditioning, n (%) | .91 | |||
| Myeloablative | 11 (42) | 11 (41) | ||
| Reduced intensity | 15 (58) | 16 (59) | ||
| Donor, n (%) | .21 | |||
| Related | 17 (65) | 13 (48) | ||
| Unrelated | 9 (35) | 14 (52) | ||
| GVHD ppx, n (%) | .40 | |||
| CNI/MTX | 13 (50) | 17 (63) | ||
| CNI/ATG/ MTX | 7 (27) | 5 (19) | ||
| CNI/Siro ± MTX | 4 (15) | 5 (19) | ||
| Other* | 2 (8) | 0 (0) | ||
| Day of sample after HCT or DLI, median (range) | 47 (23-183) | 73 (20-98) | .14 | |
| GVHD | Gut (n = 12) | Skin (n = 14) | ||
| Grade 1 | 1 | 0 | ||
| Grade 2 | 8 | 6 | ||
| Grade 3 | 0 | 8 | ||
| Grade 4 | 3 | 0 | ||
ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CNI, calcineurin inhibitor, specifically cyclosporine or tacrolimus; DLI, donor leukocyte infusion; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; MTX, methotrexate; ppx, prophylaxis; and Siro, sirolimus.
For other GVHD prophylaxis regimens, 2 patients received alemtuzumab during conditioning. One patient received tacrolimus after HCT and the other received mycophenolate mofetil alone.